Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

26.3%

5 terminated/withdrawn out of 19 trials

Success Rate

44.4%

-42.1% vs industry average

Late-Stage Pipeline

32%

6 trials in Phase 3/4

Results Transparency

125%

5 of 4 completed trials have results

Key Signals

8 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

8(50.0%)

Phase 3

5(31.3%)

Phase 4

1(6.3%)

Early Phase 1

1(6.3%)

Phase 1

1(6.3%)

16Total

Phase 2(8)

Phase 3(5)

Phase 4(1)

Early Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT06285825Phase 2Recruiting

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

Role: collaborator

NCT04516967Phase 3Completed

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

Role: lead

NCT05369208Phase 3Completed

Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP

Role: lead

NCT07447817Phase 2Not Yet Recruiting

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

Role: collaborator

NCT07033598Phase 2Recruiting

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

Role: collaborator

NCT05277272Recruiting

INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)

Role: collaborator

NCT07362225Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Role: collaborator

NCT07244419Early Phase 1Recruiting

Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients

Role: collaborator

NCT06986174Phase 2Recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Role: collaborator

NCT05787574Phase 2Recruiting

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Role: collaborator

NCT07197307Phase 2Not Yet Recruiting

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Role: collaborator

NCT06159491Phase 1Recruiting

Pacritinib in CMML

Role: collaborator

NCT04638829Phase 4Completed

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

Role: lead

NCT03554759Terminated

Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure

Role: lead

NCT03471078Phase 3Completed

Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

Role: lead

NCT04312789Phase 2Withdrawn

Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant

Role: collaborator

NCT05046327Phase 3Withdrawn

Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months

Role: lead

NCT04437953Phase 2Withdrawn

Avatrombopag for Thrombocytopenia in People With Cancer

Role: collaborator

NCT03326843Phase 3Terminated

Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

Role: lead

All 19 trials loaded